{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:57:42Z","timestamp":1792540662181,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.bioorg.2025.108824","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T16:22:52Z","timestamp":1755620572000},"page":"108824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dual inhibition of AXL and MER kinase: scope for lung and breast cancer therapeutics"],"prefix":"10.1016","volume":"164","author":[{"given":"Balaji Dashrath","family":"Sathe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav Shivaji","family":"Mane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Mudududdla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Baell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shareen","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.K.","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damodara N.","family":"Kommi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Bushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish R.","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.bioorg.2025.108824_bb0005","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1038\/onc.2012.355","article-title":"Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer","volume":"32","author":"Linger","year":"2013","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108824_bb0010","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","article-title":"Smith, Challenges and opportunities in cancer drug resistance","volume":"121","author":"Ward","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2025.108824_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.598477","article-title":"A potent and selective dual inhibitor of AXL and MERTK possesses both immunomodulatory and tumor-targeted activity","volume":"10","author":"Rios-Doria","year":"2020","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108824_bb0020","first-page":"5016","article-title":"axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase","volume":"11","author":"O\u2019Bryan","year":"1991","journal-title":"Mol. Cell. Biol."},{"issue":"47","key":"10.1016\/j.bioorg.2025.108824_bb0025","doi-asserted-by":"crossref","first-page":"30022","DOI":"10.1074\/jbc.271.47.30022","article-title":"Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases","volume":"271","author":"Nagata","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108824_bb0030","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/sj.leu.2401484","article-title":"Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"13","author":"Rochlitz","year":"1999","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bioorg.2025.108824_bb0035","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1593\/neo.05640","article-title":"Expression of axl in lung adenocarcinoma and correlation with tumor progression","volume":"7","author":"Shieh","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.bioorg.2025.108824_bb0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","article-title":"TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer","volume":"100","author":"Linger","year":"2008","journal-title":"Adv. Cancer Res."},{"issue":"17","key":"10.1016\/j.bioorg.2025.108824_bb0045","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1038\/sj.onc.1201039","article-title":"Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation","volume":"14","author":"Chen","year":"1997","journal-title":"Oncogene"},{"issue":"Pt 3","key":"10.1016\/j.bioorg.2025.108824_bb0050","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1042\/BJ20040859","article-title":"A novel site contributing to growth-arrest-specific gene 6 binding to its receptors as revealed by a human monoclonal antibody","volume":"387","author":"Fisher","year":"2005","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108824_bb0055","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.mcn.2006.06.011","article-title":"TAM receptor function in the retinal pigment epithelium","volume":"33","author":"Prasad","year":"2006","journal-title":"Mol. Cell. Neurosci."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108824_bb0060","first-page":"583","article-title":"Role of Gas6 in erythropoiesis and anemia in mice","volume":"118","author":"Angelillo-Scherrer","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108824_bb0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3324\/haematol.13635","article-title":"TAM receptors and the regulation of erythropoiesis in mice","volume":"94","author":"Tang","year":"2009","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108824_bb0070","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/eji.200324076","article-title":"The mer receptor tyrosine kinase: expression and function suggest a role in innate immunity","volume":"33","author":"Behrens","year":"2003","journal-title":"Eur. J. Immunol."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108824_bb0075","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/ni1353","article-title":"Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases","volume":"7","author":"Caraux","year":"2006","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108824_bb0080","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3390\/cancers13071521","article-title":"The role of the receptor tyrosine kinase Axl in carcinogenesis and development of therapeutic resistance: An overview of molecular mechanisms and future applications","volume":"13","author":"Wium","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108824_bb0085","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/0008-5472.CAN-20-2066","article-title":"Axl and Mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host antitumor immunity","volume":"81","author":"Davra","year":"2021","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108824_bb0090","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/cancers14030466","article-title":"AXL receptor tyrosine kinase as a promising therapeutic target directing multiple aspects of cancer progression and metastasis","volume":"14","author":"Goyette","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108824_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12079-020-00580-5","article-title":"Signaling, A pathway map of AXL receptor-mediated signaling network","volume":"15","author":"Dagamajalu","year":"2021","journal-title":"J Cell Commun Signal."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108824_bb0100","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.bioorg.2025.108824_bb0105","doi-asserted-by":"crossref","first-page":"7570","DOI":"10.1158\/0008-5472.CAN-10-1267","article-title":"AXL is an essential factor and therapeutic target for metastatic ovarian cancer","volume":"70","author":"Rankin","year":"2010","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108824_bb0110","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.3390\/cancers13225639","article-title":"Targeting MERTK and AXL in EGFR mutant non-small cell lung cancer","volume":"13","author":"Yan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108824_bb0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11912-017-0579-4","article-title":"Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies","volume":"19","author":"Schoumacher","year":"2017","journal-title":"Curr. Oncol. Rep."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108824_bb0120","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.3390\/cancers13194864","article-title":"AXL receptor in cancer metastasis and drug resistance: when normal functions go askew","volume":"13","author":"Auyez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"38","key":"10.1016\/j.bioorg.2025.108824_bb0125","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1038\/onc.2010.268","article-title":"An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies","volume":"29","author":"Ye","year":"2010","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.bioorg.2025.108824_bb0130","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1158\/0008-5472.CAN-05-0993","article-title":"Multiple roles for the receptor tyrosine kinase axl in tumor formation","volume":"65","author":"Holland","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108824_bb0135","series-title":"AXL kinase inhibitors-A prospective model for medicinal chemistry strategies in anticancer drug discovery","first-page":"188786","author":"Malvankar","year":"2022"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108824_bb0140","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/14728222.2010.515980","article-title":"Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors","volume":"14","author":"Linger","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"issue":"12","key":"10.1016\/j.bioorg.2025.108824_bb0145","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","article-title":"The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"20","key":"10.1016\/j.bioorg.2025.108824_bb0150","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.18632\/oncotarget.2542","article-title":"AXL kinase as a novel target for cancer therapy","volume":"5","author":"Wu","year":"2014","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.bioorg.2025.108824_bb0155","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.drudis.2020.09.022","article-title":"Therapeutic aspects of the Axl\/Gas6 molecular system","volume":"25","author":"Di Stasi","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108824_bb0160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-023-00846-8","article-title":"Therapeutic targeting of the functionally elusive TAM receptor family","volume":"23","author":"Miao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2025.108824_bb0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.ircmb.2021.02.002","article-title":"Tyro3, Axl, Mertk receptor-mediated efferocytosis and immune regulation in the tumor environment","volume":"361","author":"Zhou","year":"2021","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108824_bb0170","article-title":"Immune evasion mechanism and AXL, Front","volume":"11","author":"Son","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.bioorg.2025.108824_bb0175","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jmgm.2017.05.007","article-title":"Modelling, Promiscuity and selectivity of small-molecule inhibitors across TAM receptor tyrosine kinases in pediatric leukemia","volume":"75","author":"Liu","year":"2017","journal-title":"J Mol Graph Model."},{"issue":"38","key":"10.1016\/j.bioorg.2025.108824_bb0180","doi-asserted-by":"crossref","first-page":"15705","DOI":"10.1074\/jbc.M116.771485","article-title":"The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase","volume":"292","author":"Gajiwala","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"29","key":"10.1016\/j.bioorg.2025.108824_bb0185","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1038\/onc.2012.355","article-title":"Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer","volume":"32","author":"Linger","year":"2013","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108824_bb0190","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1023\/A:1011126330233","article-title":"Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast","volume":"12","author":"Berclaz","year":"2001","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108824_bb0195","first-page":"361","article-title":"Expression profile of tyrosine kinases in breast cancer","volume":"8","author":"Meric","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108824_bb0200","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/imr.12522","article-title":"TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy","volume":"276","author":"Akalu","year":"2017","journal-title":"Immunol. Rev."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108824_bb0205","doi-asserted-by":"crossref","first-page":"9206","DOI":"10.18632\/oncotarget.3280","article-title":"Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib","volume":"6","author":"Xie","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108824_bb0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2407-10-29","article-title":"Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model","volume":"10","author":"Koskimaki","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2025.108824_bb0215","series-title":"The TAM Receptor Family","first-page":"53","author":"Lemke","year":"2015"},{"issue":"11","key":"10.1016\/j.bioorg.2025.108824_bb0220","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/cancers8110101","article-title":"Targeting the TAM receptors in leukemia","volume":"8","author":"Huey","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.108824_bb0225","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.869676","article-title":"Dissecting the role of AXL in cancer immune escape and resistance to immune checkpoint inhibition","volume":"13","author":"Engelsen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.108824_bb0230","series-title":"Modulation of the Head and Neck Cancer Tumor Immune Microenvironment by the TAM Family of Receptor Tyrosine Kinases","author":"Kostecki","year":"2024"},{"issue":"12","key":"10.1016\/j.bioorg.2025.108824_bb0235","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-17-0189","article-title":"Molecular pathways: oncologic pathways and their role in T-cell exclusion and immune evasion\u2014a new role for the AXL receptor tyrosine kinase","volume":"23","author":"Aguilera","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.bioorg.2025.108824_bb0240","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2174\/1568026619666190620155613","article-title":"Research progress of Axl inhibitors","volume":"19","author":"Sun","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108824_bb0245","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.3390\/cancers14102488","article-title":"Two-front war on cancer\u2014Targeting TAM receptors in solid tumour therapy","volume":"14","author":"Mikolajczyk","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108824_bb0250","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3390\/cancers13061195","article-title":"Tam Receptor inhibition\u2013implications for cancer and the immune system","volume":"13","author":"Aehnlich","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108824_bb0255","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrclinonc.2009.128","article-title":"Neurological adverse effects caused by cytotoxic and targeted therapies","volume":"6","author":"Schiff","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108824_bb0260","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.03385","article-title":"Differential TAM receptor\u2013ligand\u2013phospholipid interactions delimit differential TAM bioactivities","volume":"3","author":"Lew","year":"2014","journal-title":"Elife"},{"issue":"22","key":"10.1016\/j.bioorg.2025.108824_bb0265","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.3390\/cancers13225695","article-title":"Kinase inhibitors\u2019 effects on innate immunity in solid cancers","volume":"13","author":"Peng","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108824_bb0270","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/0008-5472.CAN-18-2022","article-title":"Immuno-oncological efficacy of RXDX-106, a novel TAM (TYRO3, AXL, MER) family small-molecule kinase inhibitor","volume":"79","author":"Yokoyama","year":"2019","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108824_bb0275","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","article-title":"R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread\u00a0and prolongs survival in models of metastatic breast cancer","volume":"70","author":"Holland","year":"2010","journal-title":"Cancer Res."},{"issue":"12_Supplement","key":"10.1016\/j.bioorg.2025.108824_bb0280","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1158\/1538-7445.AM2022-3339","article-title":"MRX-2843, a dual MERTK and FLT3 inhibitor, mediates synergistic anti-leukemia activity in combination with BCL-2 inhibitors in acute myeloid leukemia and early T-cell precursor acute lymphoblastic leukemia","volume":"82","author":"Thapa","year":"2022","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108824_bb0285","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/hed.27340","article-title":"Dual Axl\/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti\u2010PDL1 efficacy in head and neck cancer","volume":"45","author":"Kostecki","year":"2023","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108824_bb0290","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1038\/ncomms13898","article-title":"Reprogramming the immunological microenvironment through radiation and targeting Axl","volume":"7","author":"Aguilera","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108824_bb0295","doi-asserted-by":"crossref","first-page":"1121120","DOI":"10.3389\/fonc.2022.1121120","article-title":"Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control","volume":"12","author":"Pyo","year":"2023","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108824_bb0300","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nri2303","article-title":"Immunobiology of the TAM receptors","volume":"8","author":"Lemke","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108824_bb0305","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.4049\/jimmunol.1600793","article-title":"Opposing roles of tyrosine kinase receptors Mer and Axl determine clinical outcomes in experimental immune-mediated nephritis","volume":"197","author":"Zhen","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.bioorg.2025.108824_bb0310","doi-asserted-by":"crossref","first-page":"1079041","DOI":"10.3389\/fonc.2023.1079041","article-title":"Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target","volume":"13","author":"Pidkovka","year":"2023","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bioorg.2025.108824_bb0315","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25104","article-title":"Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108824_bb0320","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1158\/1535-7163.MCT-13-1083","article-title":"Axl kinase as a key target for oncology: focus on small molecule inhibitors","volume":"13","author":"Feneyrolles","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108824_bb0325","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/mt.2012.163","article-title":"Targeting Axl with an high-affinity inhibitory aptamer","volume":"20","author":"Cerchia","year":"2012","journal-title":"Mol. Ther."},{"issue":"47","key":"10.1016\/j.bioorg.2025.108824_bb0330","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1038\/onc.2013.487","article-title":"Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy","volume":"33","author":"Leconet","year":"2014","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108824_bb0335","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/blood-2009-12-257154","article-title":"Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma","volume":"116","author":"Liu","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bioorg.2025.108824_bb0340","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2025.108824_bb0345","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2174\/0929867323666160405112954","article-title":"Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells","volume":"23","author":"Corno","year":"2016","journal-title":"Curr. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108824_bb0350","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase\u2013ligand interaction space","volume":"57","author":"Van Linden","year":"2014","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2025.108824_bb0355","doi-asserted-by":"crossref","first-page":"9683","DOI":"10.1021\/jm401387j","article-title":"Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors","volume":"56","author":"Zhang","year":"2013","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108824_bb0360","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1021\/jm500749d","article-title":"UNC2025, a potent and orally bioavailable MER\/FLT3 dual inhibitor","volume":"57","author":"Zhang","year":"2014","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2025.108824_bb0365","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1021\/jm500749d","article-title":"UNC2025, a potent and orally bioavailable MER\/FLT3 dual inhibitor","volume":"57","author":"Zhang","year":"2014","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108824_bb0370","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1134\/S1070363223100195","article-title":"Current Developments of Pyrrolo [2, 3-d] pyrimidines with Anticancer Potential (A Review)","volume":"93","author":"Tan","year":"2023","journal-title":"Russ. J. Gen. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108824_bb0375","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85630","article-title":"The MERTK\/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia","volume":"1","author":"Minson","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.bioorg.2025.108824_bb0380","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1158\/1538-7445.AM2022-3339","article-title":"MRX-2843, a dual MERTK and FLT3 inhibitor, mediates synergistic anti-leukemia activity in combination with BCL-2 inhibitors in acute myeloid leukemia and early T-cell precursor acute lymphoblastic leukemia, 82(12_Supplement)","author":"Thapa","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108824_bb0385","series-title":"Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor","author":"Yan","year":"2020"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108824_bb0390","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/jm801586s","article-title":"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily","volume":"52","author":"Schroeder","year":"2009","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108824_bb0395","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/jm801586s","article-title":"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily","volume":"52","author":"Schroeder","year":"2009","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108824_bb0400","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10585-011-9447-z","article-title":"Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation","volume":"29","author":"Dai","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"issue":"15","key":"10.1016\/j.bioorg.2025.108824_bb0405","article-title":"Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors","volume":"39","author":"Subbiah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2025.108824_bb0410","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/1538-7445.AM2021-1735","article-title":"The potent and selective MERTK\/AXL inhibitor PF-5807\/ARRY-067 activates dendritic cells to cross-prime CD8+ T cells for anti-tumor activity, 81(13_Supplement)","author":"Wong","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108824_bb0415","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ejmech.2019.06.033","article-title":"2, 7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development","volume":"178","author":"Zhuo","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.bioorg.2025.108824_bb0420","article-title":"Sitravatinib potentiates immune checkpoint blockade in refractory cancer models, JCI","volume":"3","author":"Du","year":"2018","journal-title":"Insight"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108824_bb0425","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.18632\/oncotarget.6547","article-title":"Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma","volume":"7","author":"Patwardhan","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108824_bb0430","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1021\/acsmedchemlett.3c00206","article-title":"Discovery of Novel, Thienopyridine-Based Tyrosine Kinase Inhibitors Targeting Tumorigenic RON Splice Variants","volume":"14","author":"Ryu","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"7493","key":"10.1016\/j.bioorg.2025.108824_bb0435","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature12998","article-title":"The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells","volume":"507","author":"Paolino","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.108824_bb0440","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s12272-019-01167-4","article-title":"Phosphatidylserine receptor-targeting therapies for the treatment of cancer","volume":"42","author":"Park","year":"2019","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2025.108824_bb0445","first-page":"465","article-title":"Metastasis","author":"Maru","year":"2021","journal-title":"Therapeutic Potential"},{"key":"10.1016\/j.bioorg.2025.108824_bb0450","unstructured":"C. Schultz-Fademrecht, B. Klebl, A. Choidas, U. Koch, J. Eickhoff, A. Wolf, A. Ullrich, Pharmaceutically active compounds as Axl inhibitors, Google Patents WO2012028332A8, (2015)."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108824_bb0455","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1158\/1535-7163.MCT-13-0075","article-title":"S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab","volume":"12","author":"Burbridge","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2025.108824_bb0460","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1158\/1538-7445.AM2014-4403","article-title":"Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models, 74(19_Supplement)","author":"Yan","year":"2014","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108824_bb0465","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1002\/mc.22449","article-title":"Targeting c\u2010MET by LY2801653 for treatment of cholangiocarcinoma","volume":"55","author":"Barat","year":"2016","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.bioorg.2025.108824_bb0470","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10637-012-9912-9","article-title":"LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models","volume":"31","author":"Yan","year":"2013","journal-title":"Investig. New Drugs"},{"issue":"9","key":"10.1016\/j.bioorg.2025.108824_bb0475","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-19-2321","article-title":"ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non\u2013Small Cell Lung Cancer","volume":"26","author":"Okura","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"13_Supplement","key":"10.1016\/j.bioorg.2025.108824_bb0480","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-1883","article-title":"A novel Axl and Mertk dual inhibitor ONO-7475: A new therapeutic agent for the treatment of FLT3-ITD and-wild-type acute myeloid leukemia (AML) overexpressing","volume":"78","author":"Tanaka","year":"2018","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108824_bb0485","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3324\/haematol.2017.168856","article-title":"Anexelekto\/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms","volume":"102","author":"Ruvolo","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bioorg.2025.108824_bb0490","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/blood-2019-128626","article-title":"AXL\/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells","volume":"134","author":"Post","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108824_bb0495","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/00304948.2019.1615362","article-title":"A new synthesis of cabozantinib","volume":"51","author":"R. Fang, B. Wang, Z. Zhao, L. Yin, H. Wang, J.J.O.P. Xu, P. International","year":"2019","journal-title":"Org. Prep. Proced. Int."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108824_bb0500","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/13543776.2022.2008356","article-title":"An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)","volume":"32","author":"Chu","year":"2022","journal-title":"Expert Opin Ther Pat."},{"key":"10.1016\/j.bioorg.2025.108824_bb0505","doi-asserted-by":"crossref","unstructured":"M. Favata, K. Lasky, Y. Lo, P. Feldman, J. Li, Y. Chen, C. Stevens, M. Ye, H. Wang, K.J.C.R. Liu, Characterization of INCB081776, a potent and selective dual AXL\/MER kinase inhibitor, 78(13_Supplement), Cancer Res. 78 (13) (2018) 3759, doi:10.1158\/1538-7445.AM2018-3759.","DOI":"10.1158\/1538-7445.AM2018-3759"},{"issue":"6","key":"10.1016\/j.bioorg.2025.108824_bb0510","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1021\/acs.jmedchem.0c01904","article-title":"Generating selective leads for Mer kinase inhibitors\u2014example of a comprehensive lead-generation strategy","volume":"64","author":"Nissink","year":"2021","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2025.108824_bb0515","doi-asserted-by":"crossref","first-page":"13524","DOI":"10.1021\/acs.jmedchem.1c00920","article-title":"Optimization of an Imidazo [1, 2-a] pyridine series to afford highly selective type I1\/2 dual Mer\/Axl Kinase inhibitors with in vivo efficacy","volume":"64","author":"McCoull","year":"2021","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2025.108824_bb0520","doi-asserted-by":"crossref","first-page":"10906","DOI":"10.1021\/acs.jmedchem.4c00400","article-title":"Discovery of dual MER\/AXL kinase inhibitors as bifunctional small molecules for inhibiting tumor growth and enhancing tumor immune microenvironment","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108824_bb0525","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1021\/acs.jmedchem.4c00148","article-title":"Discovery of novel macrocyclic MERTK\/AXL dual inhibitors","volume":"67","author":"Kong","year":"2024","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108824_bb0530","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11912-023-01392-7","article-title":"Axl inhibitors: status of clinical development","volume":"25","author":"Bhalla","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"22","key":"10.1016\/j.bioorg.2025.108824_bb0535","doi-asserted-by":"crossref","first-page":"8419","DOI":"10.3390\/ijms21228419","article-title":"AXL receptor in breast cancer: molecular involvement and therapeutic limitations","volume":"21","author":"Falcone","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108824_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2021.12658","article-title":"Novel AXL\u2011targeted agents overcome FLT3 inhibitor resistance in FLT3\u2011ITD+ acute myeloid leukemia cells","volume":"21","author":"Liu","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2025.108824_bb0545","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cellimm.2018.05.004","article-title":"A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers","volume":"331","author":"Wei","year":"2018","journal-title":"Cell. Immunol."},{"issue":"57","key":"10.1016\/j.bioorg.2025.108824_bb0550","doi-asserted-by":"crossref","first-page":"96656","DOI":"10.18632\/oncotarget.3750","article-title":"MerTK is a novel therapeutic target in gastric cancer","volume":"8","author":"Yi","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108824_bb0555","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-020-00694-8","article-title":"Signaling, Immuno-oncology: are TAM receptors in glioblastoma friends or foes?","volume":"19","author":"Zhou","year":"2021","journal-title":"Cell Commun Signal"},{"issue":"2","key":"10.1016\/j.bioorg.2025.108824_bb0560","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14728222.2021.1869212","article-title":"TAM kinase inhibition and immune checkpoint blockade\u2013a winning combination in cancer treatment?","volume":"25","author":"Msaouel","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108824_bb0565","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2217\/fon-2021-1096","article-title":"A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer","volume":"18","author":"Agarwal","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.bioorg.2025.108824_bb0570","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2021.06.004","article-title":"Targeting the mercapturic acid pathway for the treatment of melanoma","volume":"518","author":"Singhal","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2025.108824_bb0575","series-title":"The TAM receptor family in multiple myeloma","author":"Clark","year":"2023"},{"key":"10.1016\/j.bioorg.2025.108824_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1332818","article-title":"From MASH to HCC: the role of Gas6\/TAM receptors","volume":"15","author":"Apostolo","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.108824_bb0585","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.960401","article-title":"The TAM receptor tyrosine kinases Axl and Mer drive the maintenance of highly phagocytic macrophages","volume":"13","author":"Jim\u00e9nez-Garc\u00eda","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108824_bb0590","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1073\/pnas.0909333107","article-title":"Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival","volume":"107","author":"Gjerdrum","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"22","key":"10.1016\/j.bioorg.2025.108824_bb0595","doi-asserted-by":"crossref","first-page":"32678","DOI":"10.18632\/oncotarget.8724","article-title":"MERTK as a novel therapeutic target in head and neck cancer","volume":"7","author":"von M\u00e4ssenhausen","year":"2016","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.bioorg.2025.108824_bb0600","doi-asserted-by":"crossref","first-page":"10242","DOI":"10.1021\/acs.jmedchem.8b01229","article-title":"Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group","volume":"61","author":"Zhao","year":"2018","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108824_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194821","article-title":"A Novel Selective Axl\/Mer\/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment","volume":"14","author":"Jeon","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825007047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:30:41Z","timestamp":1762223441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825007047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":121,"alternative-id":["S0045206825007047"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108824","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual inhibition of AXL and MER kinase: scope for lung and breast cancer therapeutics","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108824"}}